AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT00643643 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Maraviroc (UK-427,857)
Description: 50 mg oral tablet twice daily for 10 days
Study NCT00643643 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Maraviroc (UK-427,857)
Description: 100 mg oral tablet twice daily for 10 days
Study NCT00643643 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Maraviroc (UK-427,857)
Description: 300 mg oral tablet twice daily for 10 days
Study NCT00643643 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Matching placebo oral tablet twice daily for 10 days
Study NCT04299295 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: YVOIRE Y-Solution 360
Description: Hyaluronic acid dermal filler
Study NCT04299295 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Juvéderm VOLBELLA
Description: Hyaluronic acid dermal filler
Study NCT01738971 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: rapid access
Description: Provision of box which the participant can take to local family planning clinic (contraceptive service) allowing rapid access (i.e. will be seen by a health professional for a consultation regarding contraception there and then).
Study NCT01738971 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: one month progestogen only pill
Description: Provision of 1 month supply of a progestogen only pill (levonorgestrel 35mcg - Norgeston, Bayer, UK)
Study NCT04247425 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Exercise Counseling
Description: Receive instructional guidance
Study NCT04247425 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Quality-of-Life Assessment
Description: Ancillary studies
Study NCT04247425 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Questionnaire Administration
Description: Ancillary studies
Study NCT04247425 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Resistance Training
Description: Complete progressive resistance training
Study NCT04428424 — intervention group
Intervention type: DRUG
Intervention: Enbrel
Description: As provided in real world practice
Study NCT00826124 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Epidural steroid injection
Description: Injection based solely on history and physical exam
Study NCT00826124 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Epidural steroid injection
Description: Two epidural steroid injections two weeks apart based on history, physical exam and MRI
Study NCT00826124 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Magnetic Resonance Imaging (MRI)
Description: Imaging of lumbar spine
Study NCT04100330 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Ficlatuzumab
Description: Ficlatuzumab is a selective recombinant humanized hepatocyte growth factor (HGF) inhibitory immunoglobulin G subclass 1 monoclonal antibody which blocks the MET tyrosine kinase receptor.
Study NCT04100330 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cytarabine
Description: Cytarabine is a chemotherapy agent. Chemotherapy agents are medications that kill cancer cells.
Study NCT04100330 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Cytarabine
Description: Cytarabine is a chemotherapy agent. Chemotherapy agents are medications that kill cancer cells.
Study NCT00287625 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Pulmonary rehabilitation
Description: Pulmonary rehabilitation
Study NCT03544827 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Atropine
Description: Atropine 0.01% then atropine 0.1%
Study NCT03544827 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Atropine
Description: Atropine 0.1% then atropine 0.01%
Study NCT00002827 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: bleomycin sulfate
Description: Given IV
Study NCT00002827 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: filgrastim
Description: Given IV
Study NCT00002827 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: dexrazoxane hydrochloride
Description: Given IV
Study NCT00002827 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: doxorubicin hydrochloride
Description: Given IV
Study NCT00002827 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: etoposide
Description: Given IV
Study NCT00002827 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: vincristine sulfate
Description: Given IV
Study NCT00002827 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: low-LET cobalt-60 gamma ray therapy
Study NCT00002827 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: low-LET electron therapy
Study NCT00002827 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: low-LET photon therapy
Study NCT04314440 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Music therapy
Description: An accredited music therapist will deliver 15-20 minutes of music therapy every day, 4-5 days in week one and remaining in week two to all MT participants. All participants in music therapy group will get a total of nine sessions. The lullaby twinkle twinkle little star will be sung for \~5 minutes, followed by the same songs played on acoustic guitar for \~5 minutes and another \~5 minutes of the same song sung in voice. This protocol will be followed in all 9 sessions for all infants in the experimental arm. The sound levels will be maintained at 55-65 decibels (dB) using appropriate meters. If MT is interrupted within 10 minutes then a make-up session will be delivered, assuming no discharge. In case of missed sessions and interrupted session infants will receive a maximum of 12 session.
Study NCT01564862 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: vortioxetine (Lu AA21004)
Description: Lu AA21004 capsules
Study NCT01564862 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Duloxetine
Description: Duloxetine capsules
Study NCT01564862 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo matching capsules
Study NCT02191943 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Duraphat
Description: The subjects in the control group will be the subject of personalized oral hygiene instructions on the basis of obtained indices, and will also receive a professional prophylaxis. Following this, the surfaces of the teeth in the control group involved in the trial will be treated with a fluoride varnish (Duraphat®) that will be applied with a brush to all surfaces of the teeth, working the varnish approximally with the brush. This treatment will be repeated in the comparative group at each follow-up appointment.
Study NCT02191943 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Icon approximal caries infiltration kit
Description: Carious lesions in the teeth in the test group shall be treated with the infiltrant ICON® according to the manufacturer's instructions. Step by step instructions for application are as follows:
Study NCT01493336 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: capecitabine RTD
Description: single oral dose
Study NCT01493336 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: capecitabine [Xeloda]
Description: single oral dose
Study NCT01493336 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: capecitabine [Xeloda]
Description: standard treatment
Study NCT01493336 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: capecitabine [Xeloda]
Description: standard treatment
Study NCT04245020 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Text message follow up
Description: A text message will be sent to the patient 6-8 weeks following discharge
Study NCT04245020 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Telephone follow up
Description: The patient will be followed up at 6-8 weeks following discharge with a telephone call
Study NCT04245020 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: In person follow up
Description: The patient will be followed up at 6-8 weeks following discharge in person in the outpatient department
Study NCT03988556 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Photobiomodulation using CareMin650 at 6 Joules (curative intent)
Description: CareMin650 is a photobiomodulation device which consists of a Lightbox and a light applicator to deliver red light with wavelength of 650 nm and irradiance between 10 and 50 mW/cm² to skin or mucosa.~For curative treatment, the dose to be delivered has been set at 6J/cm2. If the lesions of patients included in a curative cohort are resolved before the end of the radiotherapy period, the treatment will be applied with a preventive aim and the dose will decrease from 6 to 3J/cm2.
Study NCT03988556 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Photobiomodulation using CareMin650 at 3 Joules (prophylactic intent)
Description: CareMin650 is a photobiomodulation device which consists of a Lightbox and a light applicator to deliver red light with wavelength of 650 nm and irradiance between 10 and 50 mW/cm² to skin or mucosa.~For prophylactic treatment, the dose to be delivered has been set at 3J/cm2. If oral mucositis or radiodermatitis occurs in a patient included in a prophylactic cohort, the lesions will be treated with a curative intent and the dose will increase from 3 to 6J/cm2.
Study NCT04090112 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 10% lidocaine sprayed
Description: four puffs of 10% lidocaine sprayed at the cuff of ETT and four puffs at laryngeal inlet
Study NCT04090112 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: 2% lidocaine intravenous
Description: 15 mg/kg of 2% lidocaine intravenous injection prior to extubation
Study NCT03670953 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: IR CD-LD
Description: Active comparator - IR CD-LD
Study NCT03670953 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: IPX203 ER CD-LD
Description: Investigational formulation - ER CD-LD
Study NCT03670953 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Placebo Matching IPX203
Description: Double dummy placebo capsules
Study NCT03670953 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Placebo Matching IR CD-LD
Description: Double dummy placebo tablets
Study NCT03787472 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: JJV Investigational senofilcon A Multifocal Lens1
Description: CONTROL
Study NCT03787472 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: JJV Investigational senofilcon A Multifocal Lens2
Description: TEST
Study NCT00412750 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Telbivudine (LdT)
Description: 600 mg orally once daily for 104 weeks.
Study NCT00412750 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: peginterferon alpha-2a
Description: 180 μg subcutaneous injection once a week for 52 weeks.
Study NCT00412750 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: peginterferon alpha-2a
Description: 180 μg subcutaneous injection once a week for 52 weeks.
Study NCT00006565 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: HEPA Air Cleaner
Description: Placement of two active HEPA air cleaners in the homes of children
Study NCT00006565 — intervention group
Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: Placebo Filtration Unit
Description: Placement of inactive filtration unit in the homes
Study NCT01977781 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tacrolimus
Description: Topical bilateral application of 0.05% Tacrolimus BID for 10 weeks
Study NCT01977781 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Methylprednisolone Sodium Succinate
Description: Topical bilateral application of 0.5% methylprednisolone sodium succinate BID for 10 weeks
Study NCT01864278 — intervention group
Intervention type: DEVICE
Intervention: Lutonix Drug Coated Balloon
Description: Subject will receive treatment with the Lutonix Drug Coated Balloon
Study NCT00246532 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Morphine
Description: Patients will be given morphine sulfate oral medication until their back pain is adequately controlled.
Study NCT00246532 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Patients will receive placebo tablets.
Study NCT01084070 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Early oral feeding
Description: Within 6-24 hours after surgery the nasogastric tube will be removed and liquids and soft diet at will indicated.
Study NCT01084070 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Traditional Care
Description: They will have nasogastric tube and restriction of oral intake until the first sign of restoration of intestinal transit (first flatus or stool, whichever comes first). Since then withdrew nasogastric tube and liquid diet starts within 24 hours, then continues with soft diet.
Study NCT01084187 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Vardenafil
Description: vardenafil 20 mg on demand or vardenafil daily or placebo
Study NCT01084187 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Vardenafil
Description: vardenafil 20 mg on demand or vardenafil daily or placebo
Study NCT02600507 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lumateperone (ITI-007)
Study NCT02600507 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study NCT01932957 — intervention group
Intervention type: PROCEDURE
Group type: OTHER
Intervention: Laparotomy arm
Description: Laparotomy as standard treatment for ruptured ectopic pregnancy
Study NCT01932957 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Laparoscopy arm
Description: Laparoscopy as treatment for ruptured ectopic pregnancy
Study NCT02485145 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: A/B
Description: This arm uses the test product first, which consists of Diclofenac 3%, Baclofen 2%, Orphenadrine 5%, and Bupivacaine 2% in a VersaPro cream. This is the A arm. The B arm is the second arm, and consists of the VersaPro cream alone.
Study NCT02485145 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: The placebo, which consists of the VersaPro cream, will be utilized in the study.
Study NCT02485145 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: B/A
Description: This arm uses the placebo product first, which consists of the VersaPro cream alone. This is the B arm. The A arm is the second arm, which consists of the test product which consists of Diclofenac 3%, Baclofen 2%, Orphenadrine 5%, and Bupivacaine 2% in a VersaPro cream. This is the A arm.
Study NCT01082185 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: Ovation Abdominal Stent Graft System
Description: Endovascular implant of Abdominal Aortic Aneurysm Stent Graft
Study NCT01272310 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Hydroxychloroquine (HCQ), Pegylated Interferon Alpha-2a (Peg-IFN alpha-2a) and Ribavirin
Description: HCQ will be taken daily as an oral tablet of 200 mg b.i.d. Pegylated Interferon Alpha-2a - (180 µg) will be administered as weekly subcutaneous (s.c.) injections of 0.5 ml.~Ribavirin - will be taken daily based on the patient body weight. If body weight is \< 75 kg, the total daily dose of Copegus® is 1000 mg, administered as 400 mg (2 tablets of 200 mg, morning intake) and 600 mg (3 tablets of 200 mg, evening intake). If body weight is >= 75 kg, the total daily dose is 1200 mg administered as twice 600 mg (3 tablets of 200 mg per intake, morning and evening).
Study NCT00896675 — intervention group
Intervention type: OTHER
Intervention: proteomic profiles
Description: blood samples analysis
Study NCT02269527 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Live music
Description: Providing 1-hour live music 5 days/ week.
Study NCT02115464 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Metformin plus Chemo-radiotherapy
Description: Metformin 2000 mg a day for 12 months plus cisplatin-based chemotherapy with or without consolidation with standard radiotherapy of 60-63 Gy for 6 weeks.
Study NCT02115464 — intervention group
Intervention type: RADIATION
Group type: ACTIVE_COMPARATOR
Intervention: Chemo-radiotherapy
Description: Cisplatin-based chemotherapy with or without consolidation with standard radiotherapy of 60-63 Gy for 6 weeks.
Study NCT00643695 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Home-based walking program
Description: The exercise intervention is a 12 week home-based exercise program. Ideally Individuals will walk for 30 minutes, at a moderate intensity, a minimum of three times per week. However, the duration and relative intensity will be tailored for each individual.
Study NCT00643695 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Educational intervention
Description: Participants in the control group will receive a packet of information regarding hepatitis C
Study NCT01781221 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Alpha-Bio's GRAFT Natural Bovine Bone
Study NCT01781221 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Bio-Oss xenograft
Study NCT03807713 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: Minimally Invasive Ponto Surgery
Description: Minimally Invasive Ponto surgery is used for hearing rehabilitation using Ponto Wide Implants in patients indicated and counselled for Bone Anchored Hearing Systems.
Study NCT00971945 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Paclitaxel
Description: Solution, I.V., 100 mg/m2, Weekly for 6 of 7 weeks, Until disease progression or unacceptable toxicity became apparent
Study NCT03354663 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: TactiCath SE
Description: Ablation to achieve pulmonary vein isolation.
Study NCT02836067 — intervention group
Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Counseling
Description: Smoking cessation counseling
Study NCT02836067 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Smoking Cessation drugs
Description: Medication to aid smoking cessation
Study NCT02836067 — intervention group
Intervention type: PROCEDURE
Group type: OTHER
Intervention: Bronchoscopy
Description: Bronchoscopy
Study NCT02836067 — intervention group
Intervention type: PROCEDURE
Group type: OTHER
Intervention: Blood Draw
Description: Screening and research blood draws
Study NCT02836067 — intervention group
Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Questionnaires
Description: Behavioral questionnaires
Study NCT00554125 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: sirolimus
Description: given at an initial dose of 3 mg/m2, and adjusted over time to achieve steady-state whole-blood trough levels of approximately 5-8 ng/mL
Study NCT04720326 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tacrolimus Pill
Description: Envarsus® tablets dosed to achieve and maintain whole blood trough levels of tacrolimus within a patient-specific therapeutic range (interval of 3 ng/ml) that lies within a wider reference range of 3-12 ng/ml.
Study NCT04720326 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Tacrolimus capsule
Description: Advagraf® capsules dosed to achieve and maintain whole blood trough levels of tacrolimus within a patient-specific therapeutic range (interval of 3 ng/ml) that lies within a wider reference range of 3-12 ng/ml.
Study NCT01535781 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Tranexamic Acid
Description: 1 g of tranexamic acid as a bolus immediately before surgery 3 g of tranexamic acid in 24hours postop.
Study NCT01535781 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Identical syringe and drip used as in the intervention, to ensure blinding.
Study NCT01158482 — intervention group
Intervention type: PROCEDURE
Intervention: IVC Filter Placement or Retrieval
Description: An IVC Filter will be placed or removed using endovascular techniques.
Study NCT02417272 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Surgical treatment of cervical degenerative disc disease (CP ESP®)
Study NCT02417272 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Surgical treatment of cervical degenerative disc disease (Axelle®)
Description: Axelle®
Study NCT01525004 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: High-Dose trivalent inactivated influenza vaccine
Description: 0.5 mL of high-dose trivalent inactivated influenza vaccine, either one dose or 2 based on whether the patient has previously received standard dose trivalent inactivated influenza vaccine.
Study NCT01525004 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Standard dose trivalent inactivated influenza vaccine
Description: 0.5 mL standard dose trivalent inactivated influenza vaccine, either one dose or 2 based on whether the patient has previously received standard dose trivalent inactivated influenza vaccine
Study NCT01378312 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: AERAS 402
Description: 0.5 mL IM injection of 3 x 1010vp AERAS-402 on Study Days 0 and 28
Study NCT01378312 — intervention group
Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 0.5 mL IM injection of 0vp (Placebo) on Study Days 0 and 28
Study NCT02303379 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Continuous Endurance Training
Description: Endurance training with constant work load 31min at 65-75% Hrmax